Amicus Therapeutics, Inc.
FOLD
Peringkat dalam Saham
#3709
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Harga Saham
$14.49
Terakhir disinkronkan: 2026-04-27
Kapitalisasi Pasar
$4.55B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
80.22%
Negara
US
Perdagangan Amicus Therapeutics, Inc. (FOLD)
Kategori
Healthcare
Margin Operasi untuk Amicus Therapeutics, Inc. (FOLD)
Margin Operasi per October 2026 TTM: 8.00%
Menurut laporan keuangan dan harga saham terbaru dari Amicus Therapeutics, Inc., margin operasi saat ini (TTM) adalah 8.00%. Pada akhir 2023, margin operasi perusahaan adalah -19.33%.
Riwayat margin operasi untuk Amicus Therapeutics, Inc. dari 2003 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 8.00% | 69.85% |
| 2024 | 4.71% | -124.37% |
| 2023 | -19.33% | -68.87% |
| 2022 | -62.09% | -5.12% |
| 2021 | -65.44% | -29.99% |
| 2020 | -93.47% | -43.36% |
| 2019 | -165.03% | -54.20% |
| 2018 | -360.32% | -69.89% |
| 2017 | -1,196.82% | -67.38% |
| 2016 | -3,668.62% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -5,612.83% | -68.25% |
| 2013 | -17,680.72% | 6,049.82% |
| 2012 | -287.50% | 21.10% |
| 2011 | -237.41% | -96.08% |
| 2010 | -6,056.18% | 52,931.35% |
| 2009 | -11.42% | -96.11% |
| 2008 | -293.69% | -88.56% |
| 2007 | -2,567.54% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -95.18% |
US
|
|
| -149.01% | -118.63% |
US
|
|
| 25.57% | -96.80% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -96.40% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.